Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Cytokine Release Syndrome 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 23fludarabine 15fludarabine phosphate 10Methotrexate 10blinatumomab 9Whole-Body Irradiation 9Vincristine 7Specimen Handling 7Dexamethasone 7merphos 6Tacrolimus 6Mycophenolic Acid 6Stem Cell Transplantation 5Peripheral Blood Stem Cell Transplantation 5Mesna 5Mercaptopurine 5Melphalan 5Leukapheresis 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Cytarabine 5Cyclosporine 5Biopsy 5pegaspargase 4Prednisone 4Magnetic Resonance Spectroscopy 4Etoposide 4Calcium Dobesilate 4Busulfan 4prednylidene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × siltuximab × 30 days × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡